Trial Profile
Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL): Analysis of Real-life Data: "Snapshot" at 3 Years From the End of Ibrutinib ATU. A National Study of the FILO-LLC Group
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 15 May 2020 Status changed from active, no longer recruiting to completed.
- 29 Apr 2019 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 17 Jul 2018 Planned End Date changed from 1 Jun 2018 to 1 Aug 2018.